Leerink Raises Encompass Health Target to $126, Citing Growth Outlook
0h ago|3 min readQuick Read
Fazen Markets Editorial Desk
Collective editorial team · methodology
Encompass HealthEHC stock
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Leerink Partners raised its price target for Encompass Health (NYSE: EHC) on May 22, 2026. The new target of $126 per share reflects a bullish outlook on the company's growth trajectory in the post-acute care sector. The stock last traded at $126.15, down 0.86% on the day, and within a narrow range of its 52-week high of $126.52. This adjustment signals analyst confidence as the company navigates persistent demand for inpatient rehabilitation and home health services.
The upgrade arrives amid sustained macroeconomic pressure on healthcare labor costs and reimbursement rates. The post-acute care sector, which includes services provided after a hospital stay, remains a focal point for cost containment efforts from both government and private payers. Encompass Health, as one of the nation's largest operators of inpatient rehabilitation facilities and a growing home health segment, is directly exposed to these dynamics. The catalyst for the target increase is a reassessment of the company's ability to expand its higher-margin home health business while maintaining steady occupancy in its rehab hospitals. A comparable event occurred on April 12, 2026, when UBS upgraded the stock to 'Buy' with a $125 target, citing similar operational resilience.
Encompass Health's stock performance demonstrates its relative strength. The $126.15 price as of 11:57 UTC today is near the top of its 52-week range of $117.81 to $126.52. The company commands a market capitalization of approximately $12.5 billion. This compares favorably to the broader healthcare sector, where the Health Care Select Sector SPDR Fund (XLV) has gained 4.1% year-to-date, while EHC has advanced 8.7% over the same period. Key metrics underpinning the upgrade likely include Encompass Health's revenue growth, which has consistently outpaced inflation, and its adjusted EBITDA margin, which has held above 18% despite wage inflation pressures. The new $126 target implies a forward price-to-earnings ratio roughly 5% above the sector median, pricing in a premium for its integrated care model.
The target raise reinforces a positive view on the entire post-acute care value chain. It suggests analysts see durable demand for rehabilitation and home-based services, driven by an aging population and a preference for lower-cost care settings. Second-order beneficiaries include medical equipment suppliers like ResMed (RMD) and Insulet (PODD), which support home-based care, and managed care organizations seeking cost-effective post-discharge partners. A counter-argument is that the stock's valuation now reflects much of this optimism, leaving little room for error if quarterly earnings miss expectations or if regulatory headwinds intensify. Positioning data indicates institutional investors have been net buyers of EHC over the past quarter, with flow also moving into related ETFs like the iShares U.S. Healthcare Providers ETF (IHF).
The next significant catalyst is the company's Q2 2026 earnings report, expected in late July. Investors will scrutinize same-store revenue growth in the home health segment and updates on new facility openings. Key levels to watch include the immediate resistance at the 52-week high of $126.52; a sustained break above could trigger further momentum buying. Support is seen near the 50-day moving average, currently around $122.50. Regulatory developments from the Centers for Medicare & Medicaid Services regarding the 2027 proposed payment rules for inpatient rehab and home health, expected in the fall, will be critical for the sector's profit margins.
Encompass Health does not pay a regular dividend. The company has historically prioritized reinvesting its cash flow into growth initiatives, including the expansion of its home health segment and the construction of new inpatient rehabilitation hospitals. This growth-focused capital allocation strategy is a key reason analysts like those at Leerink are upgrading the stock, as they anticipate higher future earnings from these investments rather than immediate income returns for shareholders.
Encompass Health's closest pure-play competitor in inpatient rehabilitation is Select Medical (SEM). However, Encompass differentiates itself with its significant and growing home health operations, creating an integrated post-acute continuum. In the home health space, it competes with larger players like Amedisys (AMED) and LHC Group, though the latter was acquired. Encompass's dual model provides a competitive moat, as it can manage patient transitions from its own hospitals to its own home health services, potentially improving outcomes and capturing more of the patient's care journey.
The primary risks are regulatory and labor-related. Changes to Medicare reimbursement rates, which constitute a major portion of revenue, can directly impact profitability. The industry also faces persistent nurse and therapist shortages, driving up labor costs. A recession could temporarily reduce elective procedures that lead to rehab needs, though demand for post-acute care is generally considered less cyclical than other healthcare services. Finally, execution risk in scaling the home health business remains a key monitorable for investors.
Leerink's target hike validates Encompass Health's strategy but prices the stock near its all-time high, demanding flawless execution.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.